Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last November, and immediately made a big move: a series of three acquisitions totaling $24 billion that would give BMS a new schizophrenia drug, a targeted cancer medicine, and radiopharmaceuticals used to treat cancer.
On Thursday, Bristol released first quarter earnings and showed the price for those acquisitions. Annual sales for the quarter were $11.9 billion, a 6% increase from last year adjusted for foreign exchange rates. Its quarterly loss was negatively impacted by costs from the deals, coming in at $5.89 per share according to generally accepted accounting principles, or $4.40 per share, on an adjusted basis.
Analysts polled by Visible Alpha were expecting an adjusted loss of $3.43 per share on total sales of $11.4 billion, meaning product sales did well but the deals hurt earnings more than expected.
Click this link for the original source of this article.
Author: Matthew Herper
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.